Skip to content

Recursos de salud mental

Gestionar un trastorno hemorrágico es mucho más que gestionar los síntomas físicos del trastorno. También afecta a la salud mental. El estrés que sufren el paciente, el cuidador y toda la familia es real. A continuación encontrará algunos recursos que le ayudarán a superar el aspecto emocional de padecer un trastorno crónico.

Siempre puede ponerse en contacto con el trabajador social de su Centro de Tratamiento de Hemofilia si necesita ayuda. La asociación también está a su disposición.

Lo invitamos a que participe en la asociación y asista también a los eventos. ¡Contar con una comunidad de apoyo es una parte importante de su cuidado!

National Council for Mental Wellbeing

American Foundation For Suicide Prevention

Crisis Text Line

HFA Learning Central 

New Harbinger Publications

News from HFA

  • Word from Washington: May 2023

    Lawmakers in May devoted close attention to the role that pharmacy benefits managers (PBMs) play in our health care system.  PBMs are middlemen that create and administer drug formularies on behalf of health insurers, self-insured employers, Medicaid, and other payers. PBMs choose which drugs a plan will cover, negotiate drug prices on behalf of payers, The post Word from Washington: May 2023 appeared first on Hemophilia Federation of America.

  • Pfizer Announces Positive Results from Hemophilia A and B Trial

    Pfizer Inc. today announced their Phase 3 BASIS clinical trial evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX The post Pfizer Announces Positive Results from Hemophilia A and B Trial appeared first on Hemophilia Federation of America.

  • FDA Finalizes Blood Donor Eligibility Guidance

    On May 11, 2023, the U.S. Food and Drug Administration released final guidance providing recommendations for evaluating blood and plasma donor eligibility using individual risk-based questions. Consistent with FDA’s January 2023 proposed guidance, the final guidance eliminates time-based donation deferrals and screening questions specific to men who have sex with men (MSM) and women who have The post FDA Finalizes Blood Donor Eligibility Guidance appeared first on Hemophilia Federation of America.

  • FDA issues response to Novo Nordisk’s request for concizumab approval

    Recently Novo Nordisk received a Complete Response Letter from the Food and Drug Administration for concizumab. Concizumab was submitted for regulatory approval in the U.S. for the treatment of hemophilia A and B with inhibitors in August 2022. In the letter, the FDA requested additional information related to the monitoring and dosing of patients to The post FDA issues response to Novo Nordisk’s request for concizumab approval appeared first on Hemophilia Federation of America.

  • The HELP Copays Act moves forward – now in the Senate as well as in the House 

    Protections for people who rely on copay assistance have been a top priority for HFA and many other patient groups for several years. That effort took a big step forward in April with the introduction of a first-ever Senate version (S. 1375) of the HELP Copays Act.   Sponsored by Sens. Kaine, Marshall, Markey, and Ernst, The post The HELP Copays Act moves forward – now in the Senate as well as in the House  appeared first on Hemophilia Federation of America.